Aurinia Pharmaceuticals annual depreciation and amortization
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Aurinia Pharmaceuticals Depreciation & Amortization Growth & History (AUPH)
Aurinia Pharmaceuticals's depreciation and amortization was $19.4M for fiscal 2025.
View full Aurinia Pharmaceuticals company overviewAurinia Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $19.4M | $4,000 | +0.02% |
| 2024 | 2024-12-31 | $19.4M | $7.8M | +66.95% |
| 2023 | 2023-12-31 | $11.6M | $8.9M | +330.41% |
| 2022 | 2022-12-31 | $2.7M | −$55,000 | −1.99% |
| 2021 | 2021-12-31 | $2.8M | $1.4M | +101.39% |
| 2020 | 2020-12-31 | $1.4M | $200,000 | +17.08% |
| 2019 | 2019-12-31 | $1.2M | −$142,000 | −10.81% |
| 2018 | 2018-12-31 | $1.3M | −$143,000 | −9.82% |
| 2017 | 2017-12-31 | $1.5M | −$23,000 | −1.56% |
| 2016 | 2016-12-31 | $1.5M | — | — |
Aurinia Pharmaceuticals quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.8M | −$30,000 | −0.62% |
| Q1 2026 | 2026-03-31 | $4.8M | −$40,000 | −0.82% |
| Q4 2025 | 2025-12-31 | $4.9M | — | — |
| Q3 2025 | 2025-09-30 | $4.9M | −$28,000 | −0.57% |
| Q2 2025 | 2025-06-30 | $4.9M | $21,000 | +0.43% |
| Q1 2025 | 2025-03-31 | $4.9M | $9,000 | +0.19% |
| Q3 2024 | 2024-09-30 | $4.9M | −$869,000 | −15.08% |
| Q2 2024 | 2024-06-30 | $4.8M | $3.6M | +297.29% |
| Q1 2024 | 2024-03-31 | $4.8M | $3.6M | +298.27% |
| Q3 2023 | 2023-09-30 | $5.8M | $4.1M | +257.22% |
| Q2 2023 | 2023-06-30 | $1.2M | $32,000 | +2.70% |
| Q1 2023 | 2023-03-31 | $1.2M | $30,000 | +2.53% |
| Q3 2022 | 2022-09-30 | $1.6M | $913,000 | +130.43% |
| Q2 2022 | 2022-06-30 | $1.2M | $487,000 | +69.57% |
| Q1 2022 | 2022-03-31 | $1.2M | −$1,000 | −0.08% |
| Q3 2021 | 2021-09-30 | $700,000 | $384,000 | +121.52% |
| Q2 2021 | 2021-06-30 | $700,000 | $400,000 | +133.33% |
| Q1 2021 | 2021-03-31 | $1.2M | $890,000 | +298.66% |
| Q3 2020 | 2020-09-30 | $316,000 | — | — |
| Q2 2020 | 2020-06-30 | $300,000 | — | — |
| Q1 2020 | 2020-03-31 | $298,000 | — | — |
Aurinia Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, Aurinia Pharmaceuticals's depreciation and amortization increased from $1.4M to $19.4M, a change of $18.1M. The latest reported quarter, Q2 2026, shows $4.8M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aurinia Pharmaceuticals source filings ↗